IL185180A0 - Methods and compositions for modulating tweak and fn14 activity - Google Patents

Methods and compositions for modulating tweak and fn14 activity

Info

Publication number
IL185180A0
IL185180A0 IL185180A IL18518007A IL185180A0 IL 185180 A0 IL185180 A0 IL 185180A0 IL 185180 A IL185180 A IL 185180A IL 18518007 A IL18518007 A IL 18518007A IL 185180 A0 IL185180 A0 IL 185180A0
Authority
IL
Israel
Prior art keywords
compositions
activity
methods
tweak
modulating
Prior art date
Application number
IL185180A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36953868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL185180(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL185180A0 publication Critical patent/IL185180A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL185180A 2005-03-07 2007-08-09 Methods and compositions for modulating tweak and fn14 activity IL185180A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65933905P 2005-03-07 2005-03-07
PCT/US2006/007547 WO2006096487A2 (en) 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity

Publications (1)

Publication Number Publication Date
IL185180A0 true IL185180A0 (en) 2008-12-29

Family

ID=36953868

Family Applications (1)

Application Number Title Priority Date Filing Date
IL185180A IL185180A0 (en) 2005-03-07 2007-08-09 Methods and compositions for modulating tweak and fn14 activity

Country Status (12)

Country Link
US (2) US20080286271A1 (enExample)
EP (1) EP1853312B1 (enExample)
JP (2) JP2008531746A (enExample)
KR (3) KR20150031459A (enExample)
CN (2) CN101171035A (enExample)
AU (1) AU2006220825A1 (enExample)
BR (1) BRPI0608012A2 (enExample)
CA (1) CA2597485A1 (enExample)
IL (1) IL185180A0 (enExample)
RU (1) RU2007137060A (enExample)
WO (1) WO2006096487A2 (enExample)
ZA (1) ZA200707489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2507700A (en) * 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
CA2607697C (en) * 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP2460832A3 (en) 2005-05-27 2012-10-31 Biogen Idec MA Inc. TWEAK binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) * 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis
KR20100053607A (ko) * 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 항-ｔｗｅａｋ 수용체 항체의 치료 용도
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US20120055055A1 (en) * 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
SG188605A1 (en) * 2010-10-05 2013-04-30 Hoffmann La Roche Antibodies against human tweak and uses thereof
EP2683740B1 (en) 2011-03-10 2018-07-04 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN105779576B (zh) * 2014-12-25 2025-01-17 中国人民解放军第四军医大学 人tnfrsf12a基因的用途及其相关药物
WO2018102762A1 (en) 2016-12-02 2018-06-07 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
JP7415939B2 (ja) * 2018-10-31 2024-01-17 アステラス製薬株式会社 抗ヒトＦｎ１４抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
AU2507700A (en) * 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
DK1607402T3 (da) * 1999-03-08 2007-04-16 Genentech Inc Sammensætninger og fremgangsmåder til tumorbehandling
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
AU782067B2 (en) * 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
CA2422095A1 (en) * 2000-09-14 2002-03-21 Biogen, Inc. Tweak receptor agonists as anti-angiogenic agents
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2006052926A2 (en) * 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物

Also Published As

Publication number Publication date
CA2597485A1 (en) 2006-09-14
US20080286271A1 (en) 2008-11-20
JP2014111605A (ja) 2014-06-19
KR20150031459A (ko) 2015-03-24
WO2006096487A3 (en) 2007-09-13
KR20130089271A (ko) 2013-08-09
CN102225200A (zh) 2011-10-26
AU2006220825A2 (en) 2006-09-14
JP2008531746A (ja) 2008-08-14
BRPI0608012A2 (pt) 2009-11-03
ZA200707489B (en) 2008-12-31
AU2006220825A1 (en) 2006-09-14
WO2006096487A2 (en) 2006-09-14
EP1853312B1 (en) 2014-12-10
CN101171035A (zh) 2008-04-30
RU2007137060A (ru) 2009-04-20
US20120269808A1 (en) 2012-10-25
KR20070108537A (ko) 2007-11-12
EP1853312A2 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
IL185180A0 (en) Methods and compositions for modulating tweak and fn14 activity
IL185708A0 (en) Methods and compositions for modulating hyperstabilized c-met
ZA200804026B (en) Compositions and methods for modulating hemostasis
IL189975A0 (en) Methods of modulating neurotrophin-mediated activity
IL179241A0 (en) Compositions and methods for bone formation and remodeling
IL191072A0 (en) Therapeutic compositions and methods
GB0522287D0 (en) Method and compositions
IL211089A0 (en) Compositions and methods for cell killing
EP1940437A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF BACTERIA
IL191237A0 (en) Compositions and methods for treating thrombocytopenia
ZA200803712B (en) Methods and compositions for improving cognitive function
IL185753A0 (en) Methods and compositions for modulating vascular integrity
ZA200608932B (en) Method and compositions for epilation
ZA200804082B (en) Compositions and methods for controlling tissue factor signaling specificity
ZA200803748B (en) Nematicidal compositions and methods
ZA200803283B (en) Pharmaceutical gallium compositions and methods
EP1910415A4 (en) COMPOSITIONS AND PROCESSES FOR PROTEIN DEGREGATION
IL177104A0 (en) Methods and compositions for modulating angiogenesis
IL186095A0 (en) Methods and compositions for modulating and detecting wisp activity
GB0524927D0 (en) Compositions and method
GB0511235D0 (en) Compositions and method
GB0501348D0 (en) Compositions and methods
HK1109076A (en) Methods and compositions for modulating tweak and fn14 activity
GB2426539B (en) Sleeper
EP1917039A4 (en) METHODS AND COMPOSITIONS FOR REGENERATING JOINT CARTILAGE